Grace Kick

Dr. Grace Kick


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2026 in Biology
Verified
Journal Article
Open access
PDF file
BMBrandie Morgan-Jack
Brandie Morgan-Jack
GKGrace Kick
Grace Kick
ZLZhen Lyu
Zhen Lyu
TJTrupti Joshi
Trupti Joshi
BMBrian Mooney
Brian Mooney
RWRebecca Whiting
Rebecca Whiting
CLN2 disease is a fatal lysosomal storage disorder caused by deficiency of the lysosomal enzyme tripeptidyl peptidase 1 (TPP1), resulting in progressive neurodegeneration and non-neuronal pathology. While enzyme replacement therapy has improved disease management, there remains a critical need for objective molecular biomarkers capable of monitoring disease progression and therapeutic response. The purpose of this study was to utilize a canine model of CLN2 disease to investigate proteomic changes in cerebrospinal fluid (CSF) and in minimally invasive biofluids tears and plasma to identify candidate disease biomarkers. Untargeted proteomic analysis was conducted using these biofluids from unaffected controls and CLN2-affected dogs at presymptomatic, symptomatic, and advanced disease stages. CSF demonstrated the greatest degree of proteomic alterations over the disease progression. Proteins associated with cytoskeletal organization, synaptic signaling, lysosomal biology, mitochondrial metabolism, lipid homeostasis, and inflammatory responses were significantly altered. Tear fluid demonstrated overlapping biological themes with CSF, particularly involving mitochondrial metabolism, lysosomal function, and lipid-associated pathways. In contrast, plasma proteomic alterations were comparatively modest but supported systemic changes associated with extracellular signaling, inflammation, and lipid metabolism. Collectively, these findings demonstrate progressive and coordinated proteomic alterations across multiple biofluids in CLN2 disease that can serve as candidate biomarkers of disease progression.

8 September 2026 in Animals
Verified
Journal Article
Open access
PDF file
BMBrandie Morgan-Jack
Brandie Morgan-Jack
MKMartin L. Katz
Martin L. Katz
GKGrace Kick
Grace Kick
JCJoan Ripley Coates
Joan Ripley Coates
Canine degenerative myelopathy (DM) is a progressive, adult-onset neurodegenerative disease, with similarities to superoxide dismutase 1 (SOD1)-associated ALS. Clinical signs of DM begin with asymmetric pelvic limb general proprioceptive ataxia and spastic paresis that progresses to flaccid tetraplegia and respiratory failure. Although pelvic limb muscle atrophy and peripheral neuropathy have been reported in DM, intramuscular SOD1 accumulation and muscle spindle pathology remain incompletely characterized. This study evaluated pathological changes in the tibialis cranialis muscle of Pembroke Welsh Corgis with early- and late-stage DM and age-matched unaffected controls. Histologic stains and immunohistochemistry were used to evaluate myofiber morphology, fiber type distribution, muscle spindle integrity, and SOD1 immunoreactivity. Compared to unaffected dogs, DM-affected dogs exhibited increased SOD1 immunolabeling, greater variability in myofiber size, altered myofiber shape and packing, and fibrosis. A progressive reduction in the percentage of type I myofibers was observed without evidence of fiber type grouping. These changes were evident during early disease and became more pronounced with disease progression. Muscle spindles exhibited late-stage disruption of intrafusal myofiber organization and marked increase in SOD1 immunoreactivty. The observed alterations suggest that the muscle pathology was, at least in part, intrinsic to the muscle, rather than being secondary to neurodegeneration. Our findings demonstrate early and progressive pathological changes in the tibialis cranialis muscle, expanding our understanding of skeletal muscle involvement in DM.